Pyxis Oncology IncQ) expected to post a loss of 35 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
Pyxis Oncology IncQ) is expected to report a loss of 35 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $6.00, representing an 82.2% increase from the last closing price of $1.07. Previous earnings performance shows mixed results, with several beats and misses in the last quarters. This summary was generated on August 8, 2023.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments